| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 10
| Issue : 3 | Page : 121-123 |
|
|
Cariprazine: A complete solution for full-spectrum bipolar I disorder?
Ranjan Bhattacharyya
Department of Psychiatry, Murshidabad Medical College & Hospital, Kolkata, West Bengal, India
Correspondence Address:
Ranjan Bhattacharyya
Department of Psychiatry, Murshidabad Medical College & Hospital, 29, Anandasree, Garia, Kolkata 700084, West Bengal
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/DYPJ.DYPJ_61_21
|
|
|
Cariprazine is a partial agonist of dopamine and serotonin with high affinity for D3 receptor. There is excess endogenous dopamine both in schizophrenia and bipolar disorder. Cariprazine binds to D3/D2 receptor as antagonist and agonist in schizophrenia and bipolar depression, respectively. Thus, the dopamine pathway inhibited and stimulated in the respective cases. The United States Food and Drug Administration (USFDA) approval now covers the full-spectrum Bipolar I disorder, yet to hit the Indian market. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
